• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

    5/6/25 4:01:42 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KROS alert in real time by email

    LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended March 31, 2025.

    "In the first quarter, we reported initial topline results from the Phase 1 clinical trial of KER-065 that met key objectives and yielded valuable insights. These findings position us well as we prepare to engage with regulators with the aim of advancing KER-065 to a Phase 2 clinical trial in the first quarter of 2026," said Jasbir S. Seehra, Ph.D., Chair and Chief Executive Officer. "As our Board of Directors continues its review process to evaluate strategic alternatives to enhance stockholder value for the Company, we remain focused on the execution of our strategy and advancing the development of our pipeline of novel therapeutics. We expect to report data in the second quarter of 2025 from the Phase 2 TROPOS trial evaluating cibotercept (KER-012) in patients with pulmonary arterial hypertension and we plan to evaluate the appropriate development strategy for cibotercept following that data readout."

    First Quarter 2025 Financial Results

    Keros reported a net income of $148.5 million in the first quarter of 2025 as compared to a net loss of $43.1 million in the first quarter of 2024. The increase of $191.6 million was largely due to revenue recognized related to Keros' license agreement with Takeda Pharmaceuticals U.S.A., Inc., partially offset by increased research and development efforts as well as additional investments to support the achievement of Keros' clinical and corporate goals.

    Research and development expenses were $48.7 million for the first quarter of 2025 as compared to $38.3 million for the same period in 2024. The increase of $10.5 million was primarily due to additional research and development efforts, manufacturing activities and personnel expenses to support the advancement of Keros' pipeline.

    General and administrative expenses were $10.5 million for the first quarter of 2025 as compared to $10.3 million for the same period in 2024. The increase of $0.2 million was primarily due to an increase in other external expenses to support Keros' organizational growth.

    Keros' cash and cash equivalents as of March 31, 2025 was $720.5 million compared to $559.9 million as of December 31, 2024. Based on current operating assumptions, Keros expects that its cash and cash equivalents as of March 31, 2025 will enable Keros to fund its operating expenses and capital expenditure requirements into 2029.

    About Keros Therapeutics, Inc.

    Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. One of Keros' product candidates, cibotercept, is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros' second product candidate, KER-065, is being developed for the treatment of neuromuscular diseases. Keros' most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.

    Cautionary Note Regarding Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "enable," "expects" and "will" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros' expectations regarding its strategy, progress and timing of its clinical trials and data readouts for cibotercept and KER-065; statements concerning the intended benefits of the strategic review process; and Keros' expected cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: whether the objectives of the strategic alternative review process will be achieved; the terms, structure, benefits and costs of any strategic transaction; the timing of any transaction and whether any transaction will be consummated at all; the risk that the strategic alternatives review and its announcement could have an adverse effect on the ability of the Company to retain and hire key personnel and maintain relationships with partners, suppliers, employees, shareholders and other business relationships and on its operating results and business generally; the risk the strategic alternatives review could divert the attention and time of the Company's management; the risk of any unexpected costs or expenses resulting from the review; the risk of any litigation relating to the review; Keros' limited operating history and historical losses; Keros' ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros' dependence on the success of its product candidates, cibotercept, KER-065 and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros' ability to obtain, maintain and protect its intellectual property; and Keros' dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

    These and other risks are described more fully in Keros' filings with the Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K, filed with the SEC on February 26, 2025, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Investor Contact:

    Justin Frantz

    [email protected]

    617-221-6042

     
    KEROS THERAPEUTICS, INC.

    Condensed Consolidated Statements of Operations

    (In thousands, except share and per share data)

    (Unaudited)
     
     THREE MONTHS ENDED

    MARCH 31,
     2025   2024 
    REVENUE:   
    Service and other revenue 15,891   83 
    License revenue 195,355   — 
    Total revenue 211,246   83 
    OPERATING EXPENSES:   
    Research and development (48,709)  (38,258)
    General and administrative (10,497)  (10,308)
    Total operating expenses (59,206)  (48,566)
    INCOME (LOSS) FROM OPERATIONS 152,040   (48,483)
    OTHER INCOME (EXPENSE), NET   
    Dividend income 6,792   5,806 
    Other expense, net (338)  (437)
    Total other income, net 6,454   5,369 
    Income (loss) before income taxes 158,494   (43,114)
    Income tax provision (10,043)  — 
    Net income (loss)$148,451  $(43,114)
        
    Net income (loss) attributable to common stockholders—basic and diluted$148,451  $(43,114)
        
    Weighted-average shares of common stock outstanding — basic 40,559,355   35,685,422 
    Weighted-average shares of common stock outstanding — diluted 41,021,325   35,685,422 
        
    Net income (loss) per share of common stock — basic$3.66  $(1.21)
    Net income (loss) per share of common stock — diluted$3.62  $(1.21)



     
    KEROS THERAPEUTICS, INC.

    Condensed Consolidated Balance Sheets

    (In thousands, except share and per share data)

    (Unaudited)
     
     MARCH 31,

    2025
     DECEMBER 31,

    2024
    ASSETS   
    CURRENT ASSETS:   
    Cash and cash equivalents720,541  559,931 
    Accounts receivable17,291  2,742 
    Prepaid expenses and other current assets21,677  26,220 
    Total current assets759,509  588,893 
    Operating lease right-of-use assets18,667  19,251 
    Property and equipment, net4,473  4,237 
    Restricted cash1,449  1,449 
    Other long-term assets463  2,056 
    TOTAL ASSETS784,561  615,886 


    LIABILITIES AND STOCKHOLDERS' EQUITY
       
    CURRENT LIABILITIES:   
    Accounts payable6,636  4,602 
    Current portion of operating lease liabilities2,102  1,978 
    Accrued expenses and other current liabilities17,290  20,870 
    Deferred revenue3,308  — 
    Current tax liability10,043  — 
    Total current liabilities39,379  27,450 
    Operating lease liabilities, net of current portion16,311  16,883 
    Total liabilities55,690  44,333 
    STOCKHOLDERS' EQUITY:   
    Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of March 31, 2025 and December 31, 2024; no shares issued and outstanding—  — 
    Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 40,562,047 and 40,554,705 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively4  4 
    Additional paid-in capital1,149,195  1,140,328 
    Accumulated deficit(420,328) (568,779)
    Total stockholders' equity728,871  571,553 
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY784,561  615,886 


    Primary Logo

    Get the next $KROS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KROS

    DatePrice TargetRatingAnalyst
    1/21/2025Overweight → Neutral
    Cantor Fitzgerald
    1/17/2025$15.00Outperform → Neutral
    Wedbush
    12/16/2024$102.00 → $63.00Outperform
    Oppenheimer
    12/16/2024Buy → Neutral
    Guggenheim
    12/13/2024$100.00 → $47.00Buy
    H.C. Wainwright
    12/12/2024Buy → Hold
    TD Cowen
    12/12/2024Outperform → Mkt Perform
    William Blair
    12/12/2024Buy → Neutral
    BTIG Research
    More analyst ratings

    $KROS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Keros Reinforces Commitment to Maximizing Stockholder Value

      Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting "FOR" the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros", the "Company" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today issued the following statement in response to the misleading press release issued by ADAR1 Capital Management ("ADAR1") regarding K

      5/8/25 5:31:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

      Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth AUSTIN, Texas, May 8, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (NASDAQ:KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released a public letter to fellow Keros stockholders outlining its concerns with the Company's capital allocation decisions, strategic direction, and prolonged underperformance. In the letter, ADAR1 details the Company's alarming clinical results for two of its three drug candidates — KER-012 and KER-065

      5/8/25 2:10:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

      LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended March 31, 2025. "In the first quarter, we reported initial topline results from the Phase 1 clinical trial of KER-065 that met key objectives and yielded valuable insights. These findings position us well as we prepare to engage with regulators with the aim

      5/6/25 4:01:42 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

      SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

      2/13/24 6:38:35 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

      SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

      2/9/24 9:16:07 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

      SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

      1/26/24 5:26:51 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/11/25 9:57:19 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Leadership Updates

    Live Leadership Updates

    See more
    • Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

      LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi

      10/16/24 8:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

      LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. "On behalf of the Board, we are delighted to welcome Jean-Jacques to Keros during this pivotal phase of our growth," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "Jean-Jacques is a deeply

      5/28/24 4:01:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors

      LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. "Dr. Seth's deep industry experience and expertise in drug development, global operations and product launches will be an invaluable addition to our Board of Directors," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "We a

      4/19/23 8:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/11/25 9:57:19 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Adar1 Capital Management, Llc claimed ownership of 4,456,706 shares (SEC Form 3)

      3 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/11/25 8:58:32 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Seehra Jasbir exercised 49,367 shares at a strike of $0.30, increasing direct ownership by 20% to 302,223 units (SEC Form 4)

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/7/25 4:15:07 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Keros Therapeutics downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Keros Therapeutics from Overweight to Neutral

      1/21/25 7:51:46 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics downgraded by Wedbush with a new price target

      Wedbush downgraded Keros Therapeutics from Outperform to Neutral and set a new price target of $15.00

      1/17/25 11:09:49 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer reiterated coverage on Keros Therapeutics with a new price target

      Oppenheimer reiterated coverage of Keros Therapeutics with a rating of Outperform and set a new price target of $63.00 from $102.00 previously

      12/16/24 8:15:23 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    SEC Filings

    See more

    $KROS
    Financials

    Live finance-specific insights

    See more
    • SEC Form 10-Q filed by Keros Therapeutics Inc.

      10-Q - Keros Therapeutics, Inc. (0001664710) (Filer)

      5/6/25 4:03:48 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Keros Therapeutics, Inc. (0001664710) (Filer)

      5/6/25 4:02:46 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Keros Therapeutics Inc.

      SCHEDULE 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

      5/5/25 2:03:05 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

      LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended March 31, 2025. "In the first quarter, we reported initial topline results from the Phase 1 clinical trial of KER-065 that met key objectives and yielded valuable insights. These findings position us well as we prepare to engage with regulators with the aim

      5/6/25 4:01:42 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Announces Review of Strategic Alternatives

      Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that its Board of Directors (the "Board") has determined to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the Company. In connection with this determination, th

      4/10/25 6:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

      Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular dystrophy ("DMD") and other neuromuscular indicationsKeros plans on advancing KER-065 into a Phase 2 clinical trial in DMD, subject to positive regulatory interactionKeros to host a conference call and webcast today, March 31, 2025, at 8:00 a.m. ET LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutic

      3/31/25 6:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care